Cytos Biotechnology is dedicated to the discovery, development and commercialization
of a novel class of medicines – called Immunodrugs™. Immunodrugs™ are therapeutic
vaccines intended for use in the treatment and prevention of common chronic diseases
which afflict millions of people worldwide.

The Company’s lead program is CYT003, a novel allergen-independent Immunodrug™ with disease-modifying potential in Phase II clinical development for allergic asthma, and with potential to treat a broad range of different allergies.